AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 161 min read$MPLT

Foff Erin Pennock sold $124K of MPLT

Foff Erin Pennock (Chief Medical Officer) sold 15,355 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 ($0.12M total) on 2026-10-15.

Original reporting
SEC EDGAR · Foff Erin Pennock
Published Oct 16, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

A modest insider sell typically has limited price effect, but may be watched by short‑term traders.

02

Market read

The filing provides a small new data point for MPLT; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases could outweigh the impact of this small sale.

Relevance 4/10Novelty 4/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

Chief Medical Officer sold 15,355 shares for $124,068, reducing her stake to 296,906 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A $124k sale by a CMO is a routine transaction; impact is limited but could prompt short‑term selling.

Market effects

Sector

Minimal; does not affect broader biotech sector.

Regional

None; company is US‑based with limited market footprint.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

The sale could be unrelated to company outlook; investors may ignore it.

Key entities

  • Company
    MapLight Therapeutics, Inc.

    Biotech firm developing therapeutic candidates.

  • Person
    Foff Erin Pennock

    Chief Medical Officer of MapLight Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MPLT insider trading history →

Related articles

AUG 13
$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and

SEC EDGAR 8-K6 min